SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
NGNE reported Third Quarter 2026 results. The price and volatility reaction is pending.
NGNEearnings

Earnings reactions, page 4

Neurogene Inc. (NGNE) Q3 FY2026 earnings

November 9, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss was $29.0 million for the three months ended September 30, 2026, compared to $21.0 million for the three months ended September 30, 2025.
  • Research & Development expenses were $23.5 million for the three months ended September 30, 2026, compared to $17.2 million for the three months ended September 30, 2025.
  • General & Administrative expenses were $8.9 million for the three months ended September 30, 2026, compared to $6.6 million for the three months ended September 30, 2025.
  • Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026.

Guidance

  • Cash, cash equivalents and short-term investments are expected to fund planned operations into the first quarter of 2029.
  • Topline data from the Embolden registrational trial is anticipated in the second half of 2027.
  • Process Performance Qualification (PPQ) runs are on track to be completed by year-end 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →